Bio key international inc (BKYI)
CashFlow / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Net loss

-6,868

-4,275

-4,189

-1,857

-1,883

-2,582

3

-1,897

-306

Income from discontinued operations

-

-

-

-

-

-

-

-

342

Loss from continuing operations

-

-

-

-

-

-

-

-

-649

Derivative and warrant fair value adjustments

-

-

-

-

-

-

-

-

1,020

Allowance for doubtful accounts

720

500

500

-6

0

-

-377

386

-

Depreciation

84

52

49

42

40

28

28

31

21

Amortization of intangible assets

15

13

13

13

13

20

11

11

11

Amortization of resalable software license rights

1,513

1,510

21

0

-

-

-

-

-

Gain on derivative liabilities

-

-

12

31

157

78

-

-

-

Stock based directors fees

-

-

-

-

0

-

-

-

-

Amortization of debt discount

-

-

-

92

0

-

-

307

-

Amortization of capitalized contract costs

123

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

107

-

-

659

Stock based directors’ fees

37

32

-

-

-

-

-

-

-

Net discounts of notes payable and note receivable

-

-

-

-

-

-

-

100

-

Share and warrant-based compensation for employees and consultants

942

940

260

324

207

81

49

57

46

Stock based directors fees

-

-

167

17

-

-

-

-

-

Accounts receivable

-1,341

1,002

241

2,759

341

-320

-359

622

496

Due from factor

-53

56

16

-39

74

-187

189

-

-

Capitalized contract costs

202

-

-

-

-

-

-

-

-

Inventory

51

481

296

336

2

5

-4

-1

5

Resalable software license rights

-1,144

-74

0

12,000

0

-

-

-

-

Prepaid expenses and other

-1

33

109

-139

162

48

-33

-129

-65

Accounts payable

-17

32

-691

811

-193

-480

243

507

-159

Accrued liabilities

-139

352

-157

4

150

-255

-82

221

-77

Deferred revenue

-311

-125

256

-52

-98

19

-19

242

75

Net cash provided by (used for) operating activities

-

-

-

-15,560

-

-

-

-

-657

Net cash provided by discontinued operations

-

-

-

-

-

-

-

-

344

Net cash used for operating activities

-1,613

-2,465

-4,446

-

-2,502

-2,683

65

-523

-312

Proceeds from payment of note receivable

-

-

-

-

-

-

-

3,350

500

Purchase of intangible assets

30

60

0

-

-

-

-

-

-

Capital expenditures

52

166

52

3

18

129

-

56

9

Net cash used for investing activities

-82

-226

-52

-

-18

-129

-

3,293

530

Transfer of funds from restricted cash

-

-

-

-

-

-

-

-

-40

Net cash used for investing activities

-

-

-

-3

-

-

-

-

530

Proceeds from issuances of preferred stock

-

-

-

19,500

0

-

-

-

-

Proceeds from Issuance of common stock

1,875

2,000

1,860

0

1,595

5,649

-

-

-

Preferred dividends paid

-

-

535

0

-

-

-

125

-

Repayment of notes payable  related party

-

-

-

-

-

321

-

-

-

Proceeds from issuance of note payable

-

-

-

250

0

497

-

-

-

Repayment of note payable

-

-

-

250

0

497

25

3,612

-

Repurchase of outstanding warrants

-

-

-

-

150

-

-

-

-

Costs to issue notes, common and preferred stock

143

80

84

459

103

575

-

-

-

Net cash used for financing activities

-

-

-

19,040

-

-

-

-

-

Net cash provided by financing activities

1,731

1,919

1,240

-

1,341

4,752

-25

-3,737

-

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

35

-772

-3,259

3,477

-1,179

1,939

40

-966

217

Interest

-

-

0

-

-

-

-

-

-

Reclassification of derivative liability to additional paid-in capital

-

-

92

0

42

113

-

-

-

Reclassification of derivative liability to additional paid-in capital

-

-

92

-

-

113

-

-

-

Interest

-

-

-

100

0

77

-

-

-

Accrual of unpaid dividends on preferred stock

198

630

-

-

-

-

-

-

-

Issuance of warrants for financing raise

-

-

-

92

-

89

-

-

-

Issuance of common stock for consultancy services

-

-

-

-

-

90

-

-

-

Conversion of preferred dividends payable to common stock

-

-

0

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

0

-

-

-

-

-

-

Deemed dividend from trigger of anti-dilution provision feature

1,428

-

-

-

-

-

-

-

-

Issuance of common stock as a commitment fee for the Equity facility

-

198

0

-

-

-

-

-

-

Issuance of common stock as consulting services for the Equity facility

-

244

0

-

-

-

-

-

-

Conversion of Dividends Payable on Series A-1 Preferred Stock to Common Stock [Member]
Conversion of preferred dividends payable to common stock

356

540

-

-

-

-

-

-

-

Conversion of Dividends Payable on Series B-1 Preferred Stock to Common Stock [Member]
Conversion of preferred dividends payable to common stock

472

-

-

-

-

-

-

-

-

Conversion of Series A-1 Shares into Common Stock [Member]
Conversion of preferred stock to common stock, Converted

6,259

2,740

-

-

-

-

-

-

-

Conversion of Series B-1 Shares into Common Stock [Member]
Conversion of preferred stock to common stock

10,500

-

-

-

-

-

-

-

-